Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Introgen Therapeutics Receives European Certification of its U.S. ADVEXIN Production Facility
May 1st, 2007
Gendux AB and Introgen Therapeutics, Inc. (NASDAQ:INGN) announce today that Introgen has been certified with the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) that its facilities and production processes are compliant with European Good Manufacturing Practices for the manufacture of ADVEXIN p53 therapy. This is an important milestone for ADVEXIN's progress to licensure in the European Union. ADVEXIN is being developed in Europe and the United States for a variety of somatic and inherited cancer indications. After an audit and inspection of Introgen's facilities, clinical certification by the MHRA, which is part of the European Medicines...
Source: Cancer Weekly (2007-05-01)
|
